John T. Treace bought $266K of Treace Medical Concepts (TMCI)
Executed Sep 16 2024, disclosed Sep 17 2024, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Sep 17 2024), the stock returned +5.8% (delay-adjusted); from the execution session (Sep 16 2024), +1.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
John T. Treace (Chief Executive Officer) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Treace Medical Concepts, Inc. (TMCI). Across 4 priced purchase filings, the average 21-session return was +38.6% from execution and +34.3% from disclosure (delay-adjusted; derived). The largest single filing was $328K of TMCI (111,012 sh across 2 lots, as filed), executed May 27.
Healthcare · Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→39,944 sh × $4.44
Exec Aug 20
Filed Aug 24 · 5:00 PM ET TMCIPURCHASE Treace Medical Concepts, Inc. $118K
29,430 sh × $4.02
Exec Jun 10
Filed Jun 11 · 4:52 PM ET TMCIPURCHASE Treace Medical Concepts, Inc. $178K
50,000 sh × $3.56
Exec Jun 1
Filed Jun 1 · 4:38 PM ET TMCIPURCHASE Treace Medical Concepts, Inc. $328K
111,012 sh across 2 lots
Exec May 27
Filed May 28 · 4:33 PM ET TMCIPURCHASE Treace Medical Concepts, Inc. $282K
110,763 sh across 2 lots
Exec May 13
Filed May 14 · 5:33 PM ET TMCIPURCHASE Treace Medical Concepts, Inc. $524K
60,000 sh × $8.73
Exec Mar 4 2025
Filed Mar 4 2025 · 5:30 PM ET